Back to User profile » Dr David Hough
Papers published by Dr David Hough:
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Neuropsychiatric Disease and Treatment 2019, 15:587-602
Published Date: 21 February 2019
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Mathe}ws M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Neuropsychiatric Disease and Treatment 2018, 14:2807-2816
Published Date: 25 October 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D
Neuropsychiatric Disease and Treatment 2013, 9:1381-1392
Published Date: 20 September 2013
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Neuropsychiatric Disease and Treatment 2011, 7:93-101
Published Date: 8 March 2011